Sol-Gel Technologies Ltd.

NASDAQ:SLGL

Biotechnology

Healthcare
$53.36 +1.69%

+$1.19 today

Market cap
$174.70M
Beta
1.13
P/E (TTM)
-194.1
EPS (TTM)
-$0.37
52W Low $6.96High $97.97

Volume 0.03M

Average 0.04M

SLGL EBITDA Margin

EBITDA as a percentage of revenue.

Sol-Gel Technologies Ltd.NASDAQ: SLGL

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -3569.4%

EBITDA Margin was -3569.4% in Q1 FY2026, down 2689.8 pp from a year earlier. On a trailing-twelve-month basis it was -10.7%, up 104.7 pp year over year. Over 3 fiscal years it widened by 365.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -2101.6% for the fiscal year ending Dec 2026, down from -38.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-3569.4%-3079.4 pp QoQ
Last fiscal yearDec 2025
-38.3%+51.4 pp YoY
LTMMar 2026
-10.7%+104.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2689.8 pp-10037.1 pp-7347.3 pp
1 year+51.4 pp-2063.3 pp-2114.7 pp
3 years+365.5 pp-300.8 pp-666.4 pp
5 years+41.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-38.3%
Year-over-year change
+51.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SLGL compares with its peers on the latest reported figures

  • SLGL's LTM Mar 2026 EBITDA Margin of -10.7% is the 2nd highest of the 6 companies compared; the peer median is -265.8%.
  • Its year-over-year change of +104.7 pp is the 3rd highest of 5, against a peer median of +108.4 pp.
  • Over three fiscal years its change of +365.5 pp compares with a peer median of +1700.3 pp.
SLGL Competitors Peer median
EBITDA Margin for SLGL and competitors
Company Period LTM level YoY 3-year change
ORMPOramed Pharmaceuticals Inc.FY20253772.2% —+5140.2 pp
SLGLSol-Gel Technologies Ltd.LTM Mar 2026-10.7% +104.7 pp+365.5 pp
MGNXMacroGenics, Inc.LTM Mar 2026-32.2% -1.2 pp+32.0 pp
COYACoya Therapeutics, Inc.LTM Mar 2026-265.8% +218.0 pp—
OVIDOvid Therapeutics Inc.LTM Mar 2026-337.0% +4411.9 pp+3368.5 pp
CLNNClene Inc.LTM Mar 2026-21792.5% -14931.4 pp-5585.1 pp
ZNTLZentalis Pharmaceuticals, Inc.FY2025— ——
TLSATiziana Life Sciences LtdFY2025— ——
OKYOOKYO Pharma LimitedFY2025— ——
PLRXPliant Therapeutics, Inc.FY2025— ——
Peer median (excluding SLGL) -265.8%+108.4 pp+1700.3 pp

Competitors are the stored peer set for SLGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue31.27M3.88M1.55M11.54M19.39M
Cost of Revenue20.38M12.68M342K233K109K
Gross Profit10.89M(8.8M)(21.99M)11.31M19.39M
Gross Margin34.8%-226.6%-1414.9%98.0%100.0%
Research & Development20.38M12.68M23.54M17.8M22.8M
Selling, General & Admin8.45M7.45M7.37M5.75M4.18M
Operating Expenses7.93M7.45M7.32M23.32M26.93M
Depreciation & Amortization880K562K342K233K109K
EBITDA3.84M(15.68M)(28.96M)(10.35M)(7.43M)
EBITDA Margin12.3%-403.9%-1863.8%-89.7%-38.3%
Operating Income2.96M(16.24M)(29.31M)(12.01M)(7.54M)
Operating Margin9.5%-418.3%-1885.8%-104.1%-38.9%
Interest Income257K1.32M2.07M1.43M1.41M
Interest Expense00000
Other Income / Expenses257K1.32M2.07M1.43M1.41M
Income Before Tax3.22M(14.92M)(27.24M)(10.58M)(6.13M)
Pre-Tax Margin10.3%-384.3%-1752.8%-91.7%-31.6%
Income Tax Expense00000
Net Income3.22M(14.92M)(27.24M)(10.58M)(6.13M)
Net Margin10.3%-384.3%-1752.8%-91.7%-31.6%
EPS (Basic)1.40(0.65)(1.01)(0.38)(2.20)
EPS (Diluted)0.14(0.65)(1.01)(0.38)(2.20)
Weighted Avg Shares23.06M23.13M27.09M27.86M2.79M
Weighted Avg Shares (Diluted)23.57M23.13M27.09M27.86M2.79M

Sol-Gel Technologies Ltd.

NASDAQ:SLGL

Intrinsic Alpha fair value

Locked

Current Price

$53.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.